CH1/Ckappa Fab heavy chain
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain H; UniProt 122–235 | Non-standard monomer:Yes (specific site not provided by mmCIF) | CH1/Ckappa Fab light chain × 1 (Q7Z3Y4) SO4 SULFATE ION × 5 EDO 1,2-ETHANEDIOL × 4 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION;294 K;see publication | Resolution 1.51 Å R-free 0.227 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 5VSI | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1ZA6 The structure of an antitumor CH2-domain-deleted humanized antibody Deposited 2005-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain B
225–465(241 aa)
Chain D
225–465(241 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.2;290 K;4 M sodium formate, 1.5 mM Triton X-100 detergent, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 290K, pH 7.20
|
Resolution 2.80 Å R-free 0.296 |
| 1ZA6 The structure of an antitumor CH2-domain-deleted humanized antibody Deposited 2005-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain F
225–465(241 aa)
Chain H
225–465(241 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.2;290 K;4 M sodium formate, 1.5 mM Triton X-100 detergent, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 290K, pH 7.20
|
Resolution 2.80 Å R-free 0.296 |
| 1ZA6 The structure of an antitumor CH2-domain-deleted humanized antibody Deposited 2005-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 16 PDB declaration: hexadecameric |
Chain B
225–465(241 aa)
Chain D
225–465(241 aa)
Chain F
225–465(241 aa)
Chain H
225–465(241 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.2;290 K;4 M sodium formate, 1.5 mM Triton X-100 detergent, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 290K, pH 7.20
|
Resolution 2.80 Å R-free 0.296 |
| 1ZA6 The structure of an antitumor CH2-domain-deleted humanized antibody Deposited 2005-04-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 8 PDB declaration: octameric |
Chain B
225–465(241 aa)
Chain D
225–465(241 aa)
Chain F
225–465(241 aa)
Chain H
225–465(241 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.2;290 K;4 M sodium formate, 1.5 mM Triton X-100 detergent, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 290K, pH 7.20
|
Resolution 2.80 Å R-free 0.296 |
| 4D9L Fab structure of anti-HIV-1 gp120 V2 mAb 697 Deposited 2012-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain H
131–237(107 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;296 K;18% polyethylene glycol 8000 and 0.1 M Tris pH 8.5 , VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.48 Å R-free 0.238 |
| 4D9L Fab structure of anti-HIV-1 gp120 V2 mAb 697 Deposited 2012-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain I
131–237(107 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;296 K;18% polyethylene glycol 8000 and 0.1 M Tris pH 8.5 , VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.48 Å R-free 0.238 |
| 4D9L Fab structure of anti-HIV-1 gp120 V2 mAb 697 Deposited 2012-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain J
131–237(107 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;296 K;18% polyethylene glycol 8000 and 0.1 M Tris pH 8.5 , VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.48 Å R-free 0.238 |
| 4D9L Fab structure of anti-HIV-1 gp120 V2 mAb 697 Deposited 2012-01-11 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain K
131–237(107 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;296 K;18% polyethylene glycol 8000 and 0.1 M Tris pH 8.5 , VAPOR DIFFUSION, HANGING DROP, temperature 296K
|
Resolution 2.48 Å R-free 0.238 |
| 5O1R human Fab 5H2 bound to NHBA-C3 from Neisseria meningitidis serogroup B Deposited 2017-05-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain H
20–240(221 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293.15 K;0.1 M TRIS pH 8.0 and 1.6 M lithium sulphate
|
Resolution 2.86 Å R-free 0.222 |
| 5O1R human Fab 5H2 bound to NHBA-C3 from Neisseria meningitidis serogroup B Deposited 2017-05-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain I
20–240(221 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293.15 K;0.1 M TRIS pH 8.0 and 1.6 M lithium sulphate
|
Resolution 2.86 Å R-free 0.222 |
| 5UTZ Human IL-2/Fab complex Deposited 2017-02-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain H
128–238(111 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;295 K;100 mM sodium citrate, pH 5.0, 20% PEG6000
|
Resolution 2.75 Å R-free 0.247 |
| 5UTZ Human IL-2/Fab complex Deposited 2017-02-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain B
128–238(111 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;295 K;100 mM sodium citrate, pH 5.0, 20% PEG6000
|
Resolution 2.75 Å R-free 0.247 |
| 5UTZ Human IL-2/Fab complex Deposited 2017-02-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain F
128–238(111 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;295 K;100 mM sodium citrate, pH 5.0, 20% PEG6000
|
Resolution 2.75 Å R-free 0.247 |
| 5UTZ Human IL-2/Fab complex Deposited 2017-02-15 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain J
128–238(111 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5;295 K;100 mM sodium citrate, pH 5.0, 20% PEG6000
|
Resolution 2.75 Å R-free 0.247 |
| 5VR9 CH1/Ckappa Fab based on Matuzumab Deposited 2017-05-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
122–238(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;294 K;see publication for details
|
Resolution 2.15 Å R-free 0.244 |
| 5VR9 CH1/Ckappa Fab based on Matuzumab Deposited 2017-05-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain H
122–238(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;294 K;see publication for details
|
Resolution 2.15 Å R-free 0.244 |
| 6AL4 CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB Deposited 2017-08-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
125–238(114 aa)
Fragment:FD,FD,FD,FD
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9.1;293 K;20% PEG 3350, 0.2 M NA PHOSPHATE DIBASIC
|
Resolution 2.45 Å R-free 0.236 |
| 6AL4 CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB Deposited 2017-08-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain D
125–238(114 aa)
Fragment:FD,FD,FD,FD
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9.1;293 K;20% PEG 3350, 0.2 M NA PHOSPHATE DIBASIC
|
Resolution 2.45 Å R-free 0.236 |
| 6AL4 CRYSTAL STRUCTURE OF ANTI-CD19 ANTIBODY B43 FAB Deposited 2017-08-07 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain F
125–238(114 aa)
Fragment:FD,FD,FD,FD
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 9.1;293 K;20% PEG 3350, 0.2 M NA PHOSPHATE DIBASIC
|
Resolution 2.45 Å R-free 0.236 |
| 6APD Crystal structure of RSV F bound by AM22 and the infant antibody ADI-19425 Deposited 2017-08-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 15 PDB declaration: pentadecameric |
Chain D
123–239(117 aa)
Chain F
123–239(117 aa)
Chain H
123–239(117 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;10% PEG 4000
10% 2-propanol
0.1 M sodium citrate pH 5.5
|
Resolution 4.10 Å R-free 0.256 |
| 6B9Y Trastuzumab Fab v3 in complex with 5-phenyl meditope variant Deposited 2017-10-11 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 5 PDB declaration: pentameric |
Chain B
124–238(115 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M Tris pH 7.5, 15% PEG3350, 24 mM NaCl
|
Resolution 2.14 Å R-free 0.218 |
| 6BAH Trastuzumab Fab v3 with 5-diphenyl meditope variant Deposited 2017-10-12 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 5 PDB declaration: pentameric |
Chain B
124–238(115 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M Tris, pH 7.5, 24 mM NaCl, 15% PEG 3350
|
Resolution 1.90 Å R-free 0.194 |
| 6DC4 RSV-neutralizing human antibody AM22 Deposited 2018-05-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain H
123–239(117 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 17 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;0.02 M 1,6-Hexanediol, 0.02 M 1-Butanol, 0.02 M 1,2-Propanediol (racemic), 0.02 M 2-Propanol, 0.02 M 1,4-Butanediol, 0.02 M 1,3-Propanediol, 0.1 M MES/imidazole pH 6.5, 10% PEG 8000, 20% ethylene glycol
|
Resolution 1.70 Å R-free 0.205 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain B
123–239(117 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain E
123–239(117 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6DC5 RSV prefusion F in complex with AM22 Fab Deposited 2018-05-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Insufficient information Heteromer;Protein × 3 PDB declaration: trimeric |
Chain H
123–239(117 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 CD CADMIUM ION × 1 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;293 K;32% PEG 400, 4% PEG 3350, 0.01 M cadmium chloride, 0.1 M sodium acetate pH 5.5
|
Resolution 3.50 Å R-free 0.280 |
| 6OGE Cryo-EM structure of Her2 extracellular domain-Trastuzumab Fab-Pertuzumab Fab complex Deposited 2019-04-02 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer;Protein × 5 PDB declaration: pentameric |
Chain E
124–235(112 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 5 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 4.36 Å |
| 6VPY I33M (I3.2 mutant from CH103 Lineage) Deposited 2020-02-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
125–240(116 aa)
|
Not recorded | CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.5 M ammonium sulfate, 100 mM HEPES, pH 7.23, 5% PEG400
|
Resolution 2.36 Å R-free 0.223 |
| 6VPY I33M (I3.2 mutant from CH103 Lineage) Deposited 2020-02-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain H
125–240(116 aa)
|
Not recorded | GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;293 K;1.5 M ammonium sulfate, 100 mM HEPES, pH 7.23, 5% PEG400
|
Resolution 2.36 Å R-free 0.223 |
| 7CZR S protein of SARS-CoV-2 in complex bound with P5A-1B8_2B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain H
123–465(343 aa)
Chain J
123–465(343 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 30 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 7CZS S protein of SARS-CoV-2 in complex bound with P5A-1B8_3B Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 9 PDB declaration: nonameric |
Chain H
123–465(343 aa)
Chain I
123–465(343 aa)
Chain J
123–465(343 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 31 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.60 Å |
| 7CZX S protein of SARS-CoV-2 in complex bound with P5A-1B9 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 9 PDB declaration: nonameric |
Chain H
121–465(345 aa)
Chain I
121–465(345 aa)
Chain J
121–465(345 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 33 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 7D00 S protein of SARS-CoV-2 in complex bound with FabP5A-1B8 Deposited 2020-09-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Heteromer;Protein × 7 PDB declaration: heptameric |
Chain H
123–465(343 aa)
Chain J
123–465(343 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 28 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å |
| 8BBO SARS-CoV-2 Delta-RBD complexed with BA.2-36 Fab Deposited 2022-10-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain H
20–240(221 aa)
|
Not recorded | NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;2% (v/v) PEG400, 0.1M imidazole pH7.0 and 24% (w/v) PEG MME 5000.
|
Resolution 2.75 Å R-free 0.252 |
18 other PDB entries and 34 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | Q6GMX6_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain H; PDBConstruct 108–221; UniProt 122–235 |